Skip to main content

Table 1 Clinical characteristics

From: PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study

  M0
(N = 74)
M1
(N = 161)
Total
(N = 235)
Age (years), median (IQR) 77.3 (71.3–81.3) 74.8 (70.0–80.4) 75.1 (70.2–80.6)
BMI (kg/m2), median (IQR) 28.3 (25.7–30.9) 27.7 (25.4–30.1) 27.7 (25.5–30.4)
Gleason score at diagnosis, n (%)
  ≤ 7 32 (43.9) 55 (36.4) 87 (38.8)
  > 7 41 (56.2) 96 (63.6) 137 (61.2)
ECOG performance status, n (%)
 ECOG 0–1 66 (89.2) 147 (91.9) 213 (91.0)
 ECOG 2–3 8 (10.8) 13 (8.1) 21 (9.0)
 Locally advanced and metastatic disease at diagnosis, n (%) 7 (9.6) 63 (39.9) 70 (30.3)
 Extension of the disease at present, n (%) (multiple answers possible) 17 (24.3) 161 (100) 178 (75.7)
 Bone 0 (0) 145 (90.1) 145 (61.7)
  ≤ 5 bone metastases 0 70 (48.3) 70 (29.8)
  > 5 bone metastases 0 75 (51.7) 75 (31.9)
 Locoregional lymph nodes 17 (23.0) 48 (29.8) 65 (27.7)
 VDistant lymph nodes 0 (0) 36 (22.4) 36 (15.3)
 Visceral 0 (0) 6 (3.7) 6 (2.6)
 Lung 0 (0) 2 (33.3) 2 (33.3)
 Liver 0 (0) 2 (33.3) 2 (33.3)
 Multiple locations 0 (0) 2 (33.3) 2 (33.3)
Concomitant disease, n (%) (multiple answers possible)
 Hypertension 42 (56.8) 93 (57.8) 135 (57.4)
 Diabetes mellitus 19 (25.7) 34 (21.1) 53 (22.6)
 Obesity 19 (25.7) 31 (19.3) 50 (21.3)
 Cardiovascular disease 17 (23.0) 32 (19.9) 49 (20.9)
 Respiratory disorders 12 (16.2) 20 (12.4) 32 (13.6)
 Anaemia 7 (9.5) 17 (10.6) 24 (10.2)
 Depression 6 (8.1) 8 (5.0) 14 (6.0)
Laboratory parameters, median (IQR)
 PSA (ng/ml) 11.9 (7.1–30.2) 24.2 (6.6–63.8) 17.8 (6.8–43.3)
 Testosterone (ng/dl) 0.3 (0.1–12) 0.3 (0.1–2.5) 0.3 (0.1–5.4)
 Hb (g/dl) 13.9 (13–14.2) 13.1 (12–14) 13.4 (12.2–14.2)
 LDH (UI/I) 209 (181.3–371.5) 217.5 (173.8–323.5) 216 (178.3–349.8)
 Alkaline phosphatase (UI/I) 77.1 (58–104) 105 (75.8–176.8) 94 (70–147)
  1. BMI Body mass index, Hb Haemoglobin, IQR Interquartile range, LDH Lactate dehydrogenase, PSA Prostate-specific antigen